Protalix BioTherapeutics Reaches New 12-Month Low at $4.21 (PLX)
Protalix BioTherapeutics (NYSE:PLX)’s share price reached a new 52-week low on Tuesday, AR Network reports. The company traded as low as $4.21 and last traded at $4.28, with a volume of 176,023 shares traded. The stock had previously closed at $4.40.
Separately, analysts at Zacks downgraded shares of Protalix BioTherapeutics from an “outperform” rating to a “neutral” rating in a research note to investors on Thursday, July 18th. They now have a $5.90 price target on the stock.
Protalix BioTherapeutics has a 1-year low of $4.32 and a 1-year high of $6.73. The stock’s 50-day moving average is $4.85 and its 200-day moving average is $5.20. The company’s market cap is $395.0 million.
Protalix BioTherapeutics, Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its ProCellEx protein expression system, ProCellEx.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.